Know Where Topical Ruxolitinib Fits for Vitiligo and Eczema
January 2025
Ruxolitinib (Opzelura) 1.5% cream will be the first topical JAK inhibitor for vitiligo and mild to moderate eczema in ages 12 and up.
Vitiligo is an autoimmune condition where the immune system attacks melanin cells leading to patchy loss of skin pigment.
Ruxolitinib improves skin pigmentation in vitiligo by blocking the JAK pathway...and suppresses cytokines to reduce itching and inflammation in patients with eczema.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive